AQR Capital Management LLC Trims Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

AQR Capital Management LLC decreased its stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 14.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,241 shares of the company’s stock after selling 2,057 shares during the quarter. AQR Capital Management LLC’s holdings in ORIC Pharmaceuticals were worth $87,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. NEA Management Company LLC purchased a new stake in shares of ORIC Pharmaceuticals during the first quarter worth about $20,625,000. Price T Rowe Associates Inc. MD grew its position in shares of ORIC Pharmaceuticals by 140.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,566,736 shares of the company’s stock worth $21,543,000 after purchasing an additional 915,175 shares in the last quarter. Vanguard Group Inc. grew its position in shares of ORIC Pharmaceuticals by 27.9% during the first quarter. Vanguard Group Inc. now owns 2,882,055 shares of the company’s stock worth $39,628,000 after purchasing an additional 629,536 shares in the last quarter. First Turn Management LLC grew its position in shares of ORIC Pharmaceuticals by 38.1% during the second quarter. First Turn Management LLC now owns 1,515,960 shares of the company’s stock worth $10,718,000 after purchasing an additional 418,389 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of ORIC Pharmaceuticals by 190.2% during the second quarter. Dimensional Fund Advisors LP now owns 466,662 shares of the company’s stock worth $3,299,000 after purchasing an additional 305,860 shares in the last quarter. Hedge funds and other institutional investors own 95.05% of the company’s stock.

ORIC Pharmaceuticals Stock Up 3.3 %

ORIC opened at $9.45 on Friday. ORIC Pharmaceuticals, Inc. has a 52 week low of $5.34 and a 52 week high of $16.65. The stock’s fifty day moving average is $9.87 and its two-hundred day moving average is $9.38. The company has a market capitalization of $666.60 million, a P/E ratio of -5.40 and a beta of 1.12.

ORIC Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.03). Equities analysts anticipate that ORIC Pharmaceuticals, Inc. will post -1.8 earnings per share for the current year.

Analysts Set New Price Targets

ORIC has been the subject of a number of research reports. Oppenheimer dropped their price target on ORIC Pharmaceuticals from $17.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ORIC Pharmaceuticals in a research note on Monday, September 23rd. Stifel Nicolaus initiated coverage on ORIC Pharmaceuticals in a research note on Friday, September 6th. They set a “buy” rating and a $20.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a research note on Wednesday, September 18th. Finally, Wedbush reissued an “outperform” rating and set a $20.00 price target on shares of ORIC Pharmaceuticals in a research note on Tuesday, September 10th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $18.00.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.